Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 12/20 | 0.45 |
| ▸ | ITGAV | P06756 | 12/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.45 |
| ▸ | ITGB5 | P18084 | 2/20 | 0.34 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 3/20 | 0.33 |
| ▸ | TTR | P02766 | 1/20 | 0.33 |
| ▸ | WDR5 | P61964 | 2/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP8 | P22894 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
| ▸ | HTR1D | P28221 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23082986 | 0.96 | ITGB3 (0.44) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL23083051 | 0.93 | ITGB3 (0.51) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL23082985 | 0.89 | ITGB3 (0.50) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL23082988 | 0.89 | ITGB3 (0.50) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL23083186 | 0.85 | ITGB3 (0.40) | ITGB3ITGAVITGA2BCRBNTTR | |
| SCHEMBL23083070 | 0.85 | ITGB3 (0.41) | ITGB3ITGAVITGA2B | |
| SCHEMBL6422434 | 0.84 | ITGB3 (0.61) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL23083114 | 0.84 | ITGB3 (0.41) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL23082974 | 0.84 | ITGB3 (0.54) | ITGB3ITGAVITGA2BITGB5ITGB1 | |
| SCHEMBL23083053 | 0.83 | ITGB3 (0.54) | ITGB3ITGAVITGA2BITGB5ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210069337-A1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT | 2021-03-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210069337-A1 | INTEGRIN TARGETING LIGANDS AND USES THEREOF | ITGAV, ITGA5, ITGB5 | ITGB3 4/4885ITGAV 1/4885ITGA2B 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.